3.04
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
Big Cap Pro
Monthly Subscription
for only
|
Small Cap Pro
Monthly Subscription
for only
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Infinity Pharmaceuticals Inc | INFI | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 3.04 | 04:14:31 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.04 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
3.10 | 3.26 | 0.16 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 3.04 | USD |
Infinity Pharmaceuticals Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 195.19M | 64.21M | 44.71M | $ 3.05M | $ - | -0.82 | -5.80 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Infinity Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INFI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.80 | 3.91 | 2.92 | 3.43 | 3,344,471 | -0.76 | -20.0% |
1 Month | 3.69 | 5.98 | 2.92 | 4.18 | 7,869,866 | -0.65 | -17.62% |
3 Months | 2.22 | 5.98 | 1.91 | 3.91 | 3,814,161 | 0.82 | 36.94% |
6 Months | 1.10 | 5.98 | 0.94 | 3.52 | 2,062,195 | 1.94 | 176.36% |
1 Year | 1.17 | 5.98 | 0.60 | 3.06 | 1,226,585 | 1.87 | 159.83% |
3 Years | 1.88 | 5.98 | 0.60 | 2.65 | 630,218 | 1.16 | 61.7% |
5 Years | 5.87 | 6.965 | 0.60 | 2.49 | 789,669 | -2.83 | -48.21% |
Infinity Pharmaceuticals Description
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development. |